Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?
Community PollStarted
Which category of targeted biologic medications for psoriasis do you prefer in patients with solid organ malignancies?
47 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Harvard Medical School
Answered on
In nearly all cases, I would stop the TNF inhibitor (TNFi). Though there is no evidence that these drugs raise the risk for solid organ tumor, the clinician must tread cautiously. First, the patient may require other potentially immune-suppressive anti-cancer therapies (plus radiation in some cases)...
Join for free or sign in to see the full answer